Skip to main content

Table 3 Survival parameters - CR versus non CR after ASCT. Patients ≤ 60 years. Number of patients evaluable for treatment response = 176

From: Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001–2010: a retrospective, population based analysis

  Median Overall Survival (Months) (95% CI) Median Time to New Treatment (Months) (95% CI)
CR1 Non CR2 P- value CR Non CR P-value
Period 13 (N = 69) 92.3 (33.1–151.6) 56.1 (39.1–73.1) P = 0.04 45.4 (7.0–110.3) 36.6 (31.3–42.0) P = 0.001
Period 24 (N = 107) Not reacheda 81.0 (76.1–113.3) P = 0.001 49.7 (8.4–91.0) 29.4 (25.6–33.2) P = 0.001
Period 1 + 2 (N = 176) 133.7 (80.6–186.9) 79.3 (62.2–96.3) P = 0.001 49.7 (19.2–80.1) 31.3 (25.2–37.3) P = 0.001
  1. aMean overall survival = 112.3 months (95% CI 99.7–124.4)
  2. 1Number of CR patients: Period 1: 24/69 Period 2: 33/107
  3. 2Number of non CR patients Period 1: 45/69 Period 2: 74/107
  4. 3Period 1 = 01.01.2001–31.06.2005
  5. 4Period 2 = 01.07.2005–31.12.2009